Sequential high-dose methotrexate and fluorouracil combined with doxorubicin--a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group.

Abstract

In a prospective phase III multicenter trial, 213 patients with advanced measurable or nonmeasurable gastric cancer were randomized to receive methotrexate (MTX), fluorouracil (5-FU), and Adriamycin (doxorubicin; Farmitalia Carlo Erba, Milan, Italy) (FAMTX) or 5-FU, Adriamycin, and mitomycin (FAM). The results show a significantly superior response rate (41% v 9% [P less than .0001]), and survival (median, 42 weeks v 29 weeks [P = .004]) for FAMTX. There was a cumulative thrombocytopenia in FAM and not in FAMTX. The FAMTX protocol should be the reference treatment in future clinical trials that seek to improve the therapeutic outcome in advanced gastric cancer.

• Authors: J A Wils, H O Klein, D J Wagener, H Bleiberg, H Reis, F Korsten, T Conroy, M Fickers, S Leyvraz, M Buyse
• Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (J Clin Oncol) Vol. 9 Issue 5 Pg. 827-31 (May 1991) ISSN: 0732-183X [Print] United States
• PMID: 2016625 (Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial)

Chemical References

• Doxorubicin
• Fluorouracil
• Methotrexate

Topics

• Adult
• Aged
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Doxorubicin (administration & dosage)
• Female
• Fluorouracil (administration & dosage)
• Humans
• Male
• Methotrexate (administration & dosage)
• Middle Aged
• Neoplasm Staging
• Prospective Studies
• Remission Induction
• Stomach Neoplasms (drug therapy, mortality, pathology)
• Survival Analysis